- published: 26 Sep 2013
- views: 14612
Create your page here
Wednesday, 20 April 2016
-
remove the playlistNovartis
- remove the playlistNovartis
back to playlist
Joe Jimenez, Haas MBA 84 and CEO of Novartis, spoke to the Berkeley-Haas community about leadership and the pharmaceutical industry in his Dean's Speaker Series talk on September 24, 2013.
Reimagining Medicine. Our mission is to discover new ways to improve and extend people’s lives. We use science-based innovation to address some of society’s most challenging healthcare issues. We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible.
© 2016 Novartis AG
- published: 27 Jan 2016
- views: 1276
Telangana's Information Technology Minister K. Tarakarama Rao inaugurated the new complex of Novartis Global Service Centers (NGSC), a nine-storied structure with a gross area of 800,000 square feet, or sufficient space to enable Novartis to absorb future growth.
The other global NGSCs are in Mexico City, Dublin, Prague, Kuala Lumpur.
Download iDreamMedia app and enjoy all of these videos through your mobiles/tablets:
iPhone: http://tinyurl.com/lvu3wyx
iPad: http://tinyurl.com/ls4tee8
Android: http://tinyurl.com/m78hwyv
For More Latest Videos, please check out
Breaking News: http://goo.gl/rXYPWO
Full Movies: http://goo.gl/mDS9IQ
Film Trailers & Events: http://goo.gl/vQ6oKl
Comedy Scenes: http://goo.gl/bpCWe2
Action Scenes: http://goo.gl/Dk3JPF
- published: 23 Dec 2015
- views: 103
Each of us is different. At Novartis, we aspire to move beyond stereotypes, assumptions and bias to bring these differences together every day, so we can see the world through the eyes of our patients and customers, in our quest to make their lives longer and healthier.
For more information: http://www.novartis.com/careers/diversity-inclusion/index.shtml
(c) Novartis 2014
- published: 20 Nov 2014
- views: 12613
CEO Joseph Jimenez says oncology will be an area of great medical breakthroughs in the next five to ten years.
- published: 28 Mar 2013
- views: 1634
Die Novartis-Aktie ist am Mittwoch das grosse Thema am Schweizer Aktienmarkt. Im Video-Interview sagt CEO Joseph Jimenez, was er mit der Problemsparte Alcon vorhat und in welchen Bereichen viel Wachstum schlummert.
- published: 27 Jan 2016
- views: 144
Novartis completed about $25 billion of transactions in its product portfolios, including the sale of two units to British-based GlaxoSmithKline. Hester Plumridge explains why the Swiss company is doing these deals now and what this means for the pharmaceutical industry.
Subscribe to the WSJ channel here:
http://bit.ly/14Q81Xy
Visit the WSJ channel for more video:
https://www.youtube.com/wsjdigitalnetwork
More from the Wall Street Journal:
Visit WSJ.com: http://online.wsj.com/home-page
Follow WSJ on Facebook:
http://www.facebook.com/wsjlive
Follow WSJ on Google+: https://plus.google.com/+wsj/posts
Follow WSJ on Twitter: https://twitter.com/WSJLive
Follow WSJ on Instagram: http://instagram.com/wsj
Follow WSJ on Pinterest: http://www.pinterest.com/wsj/
Follow WSJ on Tumblr: http://www.tumblr.com/tagged/wall-street-journal
- published: 22 Apr 2014
- views: 4665
Novartis CEO Joseph Jimenez on innovation in health care, integrating GlaxoSmithKline assets and concerns over the potential regulation of pharmaceutical pricing.
Watch Maria Bartiromo talk about Health Care and Strategy on Mornings With Maria.
- published: 21 Oct 2015
- views: 197
Novartis International BioCamp 2015 shows student interactions during a 3.5 day pioneering leadership seminar at the Novartis Campus in Basel.
© 2015 Novartis AG
- published: 10 Sep 2015
- views: 2838
Novartis International Biotechnology Leadership Camp (BioCamp) is a pioneering three-day seminar that offers top university students the opportunity to apply their knowledge to current trends and challenges of the biotechnology and healthcare industry. The 2014 BioCamp welcomed over 60 participants from 25 countries to Novartis Headquarters in Basel, Switzerland, from August 25 to August 27, 2014.
Learn more about the Novartis BioCamp: http://www.novartis.com/careers/biocamp/index.shtml
- published: 05 Sep 2014
- views: 10816
Novartis International AG is a multinational pharmaceutical company based in Basel, Switzerland, ranking number two in sales (46.806 billion US$) among the world-wide industry in 2010.
Novartis manufactures such drugs as clozapine (Clozaril), diclofenac (Voltaren), carbamazepine (Tegretol), valsartan (Diovan), imatinib mesylate and (Gleevec / Glivec). Additional agents include ciclosporin (Neoral / Sandimmun), letrozole (Femara), methylphenidate (Ritalin), terbinafine (Lamisil), and others.
Renamed to Novartis following an acquisition by Ciba-Geigy, it owns Sandoz, a large manufacturer of generic drugs. The company formerly owned the Gerber Products Company, a major infant and baby products producer, but sold it to Nestlé on 1 September 2007.
Novartis is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA) and of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA).
Novartis was created in 1996 from the merger of Ciba-Geigy and Sandoz Laboratories, both Swiss companies with long histories. Ciba-Geigy was formed in 1970 by the merger of J. R. Geigy Ltd (founded in Basel in 1758) and CIBA (founded in Basel in 1859). Combining the histories of the merger partners, the company's effective history spans 250 years.
This page contains text from Wikipedia, the Free Encyclopedia -
http://en.wikipedia.org/wiki/Novartis
This article is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License, which means that you can copy and modify it as long as the entire work (including additions) remains under this license.
This article is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License, which means that you can copy and modify it as long as the entire work (including additions) remains under this license.
- Loading...
-
57:40Joe Jimenez, CEO of Novartis at Berkeley-Haas
Joe Jimenez, CEO of Novartis at Berkeley-HaasJoe Jimenez, CEO of Novartis at Berkeley-Haas
Joe Jimenez, Haas MBA 84 and CEO of Novartis, spoke to the Berkeley-Haas community about leadership and the pharmaceutical industry in his Dean's Speaker Series talk on September 24, 2013. -
3:27Long Live Life: Reflecting on the Novartis mission
Long Live Life: Reflecting on the Novartis mission -
1:17Novartis Mission
Novartis MissionNovartis Mission
Reimagining Medicine. Our mission is to discover new ways to improve and extend people’s lives. We use science-based innovation to address some of society’s most challenging healthcare issues. We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible. © 2016 Novartis AG -
11:49Inauguration of Novartis Knowledge City
Inauguration of Novartis Knowledge City -
11:41Inauguration of Novartis Knowledge City - Novartis Knowledge City || Novartis Knowledge City
Inauguration of Novartis Knowledge City - Novartis Knowledge City || Novartis Knowledge CityInauguration of Novartis Knowledge City - Novartis Knowledge City || Novartis Knowledge City
Telangana's Information Technology Minister K. Tarakarama Rao inaugurated the new complex of Novartis Global Service Centers (NGSC), a nine-storied structure with a gross area of 800,000 square feet, or sufficient space to enable Novartis to absorb future growth. The other global NGSCs are in Mexico City, Dublin, Prague, Kuala Lumpur. Download iDreamMedia app and enjoy all of these videos through your mobiles/tablets: iPhone: http://tinyurl.com/lvu3wyx iPad: http://tinyurl.com/ls4tee8 Android: http://tinyurl.com/m78hwyv For More Latest Videos, please check out Breaking News: http://goo.gl/rXYPWO Full Movies: http://goo.gl/mDS9IQ Film Trailers & Events: http://goo.gl/vQ6oKl Comedy Scenes: http://goo.gl/bpCWe2 Action Scenes: http://goo.gl/Dk3JPF -
3:33Diversity & Inclusion at Novartis
Diversity & Inclusion at NovartisDiversity & Inclusion at Novartis
Each of us is different. At Novartis, we aspire to move beyond stereotypes, assumptions and bias to bring these differences together every day, so we can see the world through the eyes of our patients and customers, in our quest to make their lives longer and healthier. For more information: http://www.novartis.com/careers/diversity-inclusion/index.shtml (c) Novartis 2014 -
3:22Why Novartis focuses on cancer drugs
Why Novartis focuses on cancer drugsWhy Novartis focuses on cancer drugs
CEO Joseph Jimenez says oncology will be an area of great medical breakthroughs in the next five to ten years. -
2:48Joseph Jimenez, CEO Novartis
Joseph Jimenez, CEO NovartisJoseph Jimenez, CEO Novartis
Die Novartis-Aktie ist am Mittwoch das grosse Thema am Schweizer Aktienmarkt. Im Video-Interview sagt CEO Joseph Jimenez, was er mit der Problemsparte Alcon vorhat und in welchen Bereichen viel Wachstum schlummert. -
3:54Novartis and Glaxo Deal Reshapes Pharma Industry
Novartis and Glaxo Deal Reshapes Pharma IndustryNovartis and Glaxo Deal Reshapes Pharma Industry
Novartis completed about $25 billion of transactions in its product portfolios, including the sale of two units to British-based GlaxoSmithKline. Hester Plumridge explains why the Swiss company is doing these deals now and what this means for the pharmaceutical industry. Subscribe to the WSJ channel here: http://bit.ly/14Q81Xy Visit the WSJ channel for more video: https://www.youtube.com/wsjdigitalnetwork More from the Wall Street Journal: Visit WSJ.com: http://online.wsj.com/home-page Follow WSJ on Facebook: http://www.facebook.com/wsjlive Follow WSJ on Google+: https://plus.google.com/+wsj/posts Follow WSJ on Twitter: https://twitter.com/WSJLive Follow WSJ on Instagram: http://instagram.com/wsj Follow WSJ on Pinterest: http://www.pinterest.com/wsj/ Follow WSJ on Tumblr: http://www.tumblr.com/tagged/wall-street-journal -
5:08Novartis CEO on partnering with Google on contact lenses
Novartis CEO on partnering with Google on contact lensesNovartis CEO on partnering with Google on contact lenses
Novartis CEO Joseph Jimenez on innovation in health care, integrating GlaxoSmithKline assets and concerns over the potential regulation of pharmaceutical pricing. Watch Maria Bartiromo talk about Health Care and Strategy on Mornings With Maria. -
5:08Novartis International BioCamp 2015
Novartis International BioCamp 2015Novartis International BioCamp 2015
Novartis International BioCamp 2015 shows student interactions during a 3.5 day pioneering leadership seminar at the Novartis Campus in Basel. © 2015 Novartis AG -
5:56Novartis International Biotechnology Leadership Camp 2014
Novartis International Biotechnology Leadership Camp 2014Novartis International Biotechnology Leadership Camp 2014
Novartis International Biotechnology Leadership Camp (BioCamp) is a pioneering three-day seminar that offers top university students the opportunity to apply their knowledge to current trends and challenges of the biotechnology and healthcare industry. The 2014 BioCamp welcomed over 60 participants from 25 countries to Novartis Headquarters in Basel, Switzerland, from August 25 to August 27, 2014. Learn more about the Novartis BioCamp: http://www.novartis.com/careers/biocamp/index.shtml -
2:53Novartis/GSK -- expensive restructuring?
Novartis/GSK -- expensive restructuring?Novartis/GSK -- expensive restructuring?
GlaxoSmithKline has struck a three-way agreement worth $16bn with Novartis to reorganise their businesses. Lex's Joseph Cotterill and Robert Armstrong discuss whether the reorganisation aids a prime objective of drugmakers: selling more drugs. For more video content from the Financial Times, visit http://www.FT.com/video Subscribe to the Financial Times on YouTube; http://goo.gl/vUQx5k Twitter https://twitter.com/ftvideo Facebook https://www.facebook.com/financialtimes -
3:04A look inside the Genomics Institute of the Novartis Research Foundation
A look inside the Genomics Institute of the Novartis Research FoundationA look inside the Genomics Institute of the Novartis Research Foundation
Genomics Institute of the Novartis Research Foundation (GNF) researchers use cutting-edge technology—including automation and robotics developed at the institute—to take advantage of emerging large-scale, data-rich fields for drug discovery.
- Acromegaly
- Acronym
- Actelion
- AD HD
- Adecco
- ADHD
- Afinitor
- Agricultural
- AIDS
- Air-conditioning
- Aktiengesellschaft
- Albert Hofmann
- Alcoholism
- Alcon
- Alexander Clavel
- Alizarine blue
- ALM Media
- Alzheimer's disease
- Anti-inflammatory
- Antidepressant
- Antipyrin
- Arthur Stoll
- Asset
- AstraZeneca
- Atrazine
- Auramine
- Baby food
- Basel
- Basel, Switzerland
- BASF
- Benefiber
- Biology
- Biotechnology
- Breast cancer
- Buckley's
- Bufferin
- Calcium-Sandoz
- Cancer
- Carbamazepine
- CEO
- Chairman
- Chelation therapy
- Chiron Corporation
- Ciba Vision
- Ciba-Geigy
- Ciclosporin
- Clariant
- Class action
- Clozapine
- Compensatory damages
- Comtan
- Comtrex
- Contact lens
- Credit Suisse
- Crisp bread
- Cyromazine
- Cystic fibrosis
- Daniel Vasella
- DDT
- Delmark
- Deracoxib
- Diabetes
- Diclofenac
- Diovan
- Diseases
- Doan's
- Dye
- Dyewood
- EFPIA
- Epilepsy
- Equity (finance)
- Ergot
- Ergotamine
- European Commission
- Everolimus
- Ex-Lax
- Excedrin
- Exjade
- FairPensions
- Femara
- Fenistil
- Financial Times
- Focalin
- Frank Gehry
- Fuchsine
- Full-time equivalent
- Gas-X
- Generic drug
- Genetically modified
- Germany
- Givaudan
- GlaxoSmithKline
- Gleevec
- Gynergen
- Habitrol
- Harvard University
- Hepatitis B
- HIV
- Hoechst AG
- Hoffmann-La Roche
- Holcim
- Human resources
- Hyderabad, India
- Hypercholesterolemia
- Hypertension
- Imatinib mesylate
- India
- Influenza research
- Influenza vaccine
- InnoMed
- InnoMed PredTox
- IntelliPharmaCeutics
- Iron
- Isostar
- Ivermectin
- Jenny Holzer
- Johann Muller-Pack
- Joseph Jimenez
- Josiphos ligands
- Julius Baer Group
- Kazuyo Sejima
- Keri
- Lambda-cyhalothrin
- Lamisil
- Lansoprazole
- Leather
- Lescol
- Letrozole
- Lipactin
- Lotrel
- Lucentis
- Lufenuron
- Maalox
- Macular degeneration
- Madras High Court
- Management
- Medical diagnosis
- Medicine
- Mental disorder
- Methylphenidate
- Miconazole
- Microbe
- Milbemycin oxime
- Nestlé
- Net income
- New York Law Journal
- NICE
- Nitenpyram
- No-doz
- Novartis
- Ovomaltine
- Oxfam
- Paper
- Paracetamol
- Parkinson's disease
- Patent
- Paul Hermann Müller
- Penciclovir
- Pesticide
- Pharmaceutical
- Portal Companies
- Praziquantel
- Pregnancy
- Psychedelic
- Psychiatry
- Psychosis
- Psychotomimetic
- Public company
- PubMed Identifier
- Punitive damages
- Rafael Moneo
- Rasilez
- Reuters
- Rhine
- Richard Serra
- Richemont
- Ritalin
- Rivastigmine
- Ryue Nishizawa
- Saccharin
- Saint Johann
- Sales representative
- Sandimmune
- Sandostatin
- Sandoz
- Schizophrenia
- Sentinel Flavor Tabs
- Sexual deviancy
- SGS S.A.
- Shanghai
- Silk
- SIX Swiss Exchange
- Specialty chemicals
- Subsidiary
- Suffern, New York
- Sweden
- Swiss Market Index
- Swiss Re
- Swisscom
- Switzerland
- Syngenta
- Synthes
- Tasigna
- Tavist
- Teepee
- Tegretol
- Telbivudine
- Terbinafine
- Termalgin
- Textile
- The Jakarta Post
- The Swatch Group
- Theraflu
- Ticker symbol
- Timothy Leary
- Tioconazole
- Tobramycin
- Tofranil
- Transocean
- Triclabendazole
- Trileptal
- UBS
- UC Berkeley
- United States dollar
- Vaccine
- Valsartan
- Veterinary medicine
- Voltaren
- Wall Street Journal
- Wasabröd
- Wikipedia Link rot
- Xylometazoline
- Zometa
-
Joe Jimenez, CEO of Novartis at Berkeley-Haas
Joe Jimenez, Haas MBA 84 and CEO of Novartis, spoke to the Berkeley-Haas community about leadership and the pharmaceutical industry in his Dean's Speaker Series talk on September 24, 2013. -
-
Novartis Mission
Reimagining Medicine. Our mission is to discover new ways to improve and extend people’s lives. We use science-based innovation to address some of society’s most challenging healthcare issues. We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible. © 2016 Novartis AG -
-
Inauguration of Novartis Knowledge City - Novartis Knowledge City || Novartis Knowledge City
Telangana's Information Technology Minister K. Tarakarama Rao inaugurated the new complex of Novartis Global Service Centers (NGSC), a nine-storied structure with a gross area of 800,000 square feet, or sufficient space to enable Novartis to absorb future growth. The other global NGSCs are in Mexico City, Dublin, Prague, Kuala Lumpur. Download iDreamMedia app and enjoy all of these videos through your mobiles/tablets: iPhone: http://tinyurl.com/lvu3wyx iPad: http://tinyurl.com/ls4tee8 Android: http://tinyurl.com/m78hwyv For More Latest Videos, please check out Breaking News: http://goo.gl/rXYPWO Full Movies: http://goo.gl/mDS9IQ Film Trailers & Events: http://goo.gl/vQ6oKl Comedy Scenes: http://goo.gl/bpCWe2 Action Scenes: http://goo.gl/Dk3JPF -
Diversity & Inclusion at Novartis
Each of us is different. At Novartis, we aspire to move beyond stereotypes, assumptions and bias to bring these differences together every day, so we can see the world through the eyes of our patients and customers, in our quest to make their lives longer and healthier. For more information: http://www.novartis.com/careers/diversity-inclusion/index.shtml (c) Novartis 2014 -
Why Novartis focuses on cancer drugs
CEO Joseph Jimenez says oncology will be an area of great medical breakthroughs in the next five to ten years. -
Joseph Jimenez, CEO Novartis
Die Novartis-Aktie ist am Mittwoch das grosse Thema am Schweizer Aktienmarkt. Im Video-Interview sagt CEO Joseph Jimenez, was er mit der Problemsparte Alcon vorhat und in welchen Bereichen viel Wachstum schlummert. -
Novartis and Glaxo Deal Reshapes Pharma Industry
Novartis completed about $25 billion of transactions in its product portfolios, including the sale of two units to British-based GlaxoSmithKline. Hester Plumridge explains why the Swiss company is doing these deals now and what this means for the pharmaceutical industry. Subscribe to the WSJ channel here: http://bit.ly/14Q81Xy Visit the WSJ channel for more video: https://www.youtube.com/wsjdigitalnetwork More from the Wall Street Journal: Visit WSJ.com: http://online.wsj.com/home-page Follow WSJ on Facebook: http://www.facebook.com/wsjlive Follow WSJ on Google+: https://plus.google.com/+wsj/posts Follow WSJ on Twitter: https://twitter.com/WSJLive Follow WSJ on Instagram: http://instagram.com/wsj Follow WSJ on Pinterest: http://www.pinterest.com/wsj/ Follow WSJ on Tumblr: http://www.tum... -
Novartis CEO on partnering with Google on contact lenses
Novartis CEO Joseph Jimenez on innovation in health care, integrating GlaxoSmithKline assets and concerns over the potential regulation of pharmaceutical pricing. Watch Maria Bartiromo talk about Health Care and Strategy on Mornings With Maria. -
Novartis International BioCamp 2015
Novartis International BioCamp 2015 shows student interactions during a 3.5 day pioneering leadership seminar at the Novartis Campus in Basel. © 2015 Novartis AG -
Novartis International Biotechnology Leadership Camp 2014
Novartis International Biotechnology Leadership Camp (BioCamp) is a pioneering three-day seminar that offers top university students the opportunity to apply their knowledge to current trends and challenges of the biotechnology and healthcare industry. The 2014 BioCamp welcomed over 60 participants from 25 countries to Novartis Headquarters in Basel, Switzerland, from August 25 to August 27, 2014. Learn more about the Novartis BioCamp: http://www.novartis.com/careers/biocamp/index.shtml -
Novartis/GSK -- expensive restructuring?
GlaxoSmithKline has struck a three-way agreement worth $16bn with Novartis to reorganise their businesses. Lex's Joseph Cotterill and Robert Armstrong discuss whether the reorganisation aids a prime objective of drugmakers: selling more drugs. For more video content from the Financial Times, visit http://www.FT.com/video Subscribe to the Financial Times on YouTube; http://goo.gl/vUQx5k Twitter https://twitter.com/ftvideo Facebook https://www.facebook.com/financialtimes -
A look inside the Genomics Institute of the Novartis Research Foundation
Genomics Institute of the Novartis Research Foundation (GNF) researchers use cutting-edge technology—including automation and robotics developed at the institute—to take advantage of emerging large-scale, data-rich fields for drug discovery. -
120 secondes - Novartis restructure son portefeuille d'activités
120 secondes : Reto Zenhäusern, membre de la direction générale de Novartis, commente l'importante transformation annoncée hier par le CEO de l'entreprise Joe Jimenez. Retrouvez toutes les vidéos de 120 secondes sur : http://www.rts.ch/couleur3/programmes/120-secondes Retrouvez la Radio Télévision Suisse: Site internet : http://www.rts.ch/ Facebook : https://www.facebook.com/rts.ch Twitter : https://twitter.com/radiotelesuisse Instagram : http://instagram.com/radiotelevisionsuisse Google+ : https://plus.google.com/+RadioTelevisionSuisse/posts -
Annual Press Conference 2015 - Novartis AG
Novartis AG today announced its financial results for the fourth quarter and full year ended December 31, 2014. Watch the entire Press Conference with speeches from CEO Joseph Jimenez, CFO Harry Kirsch and Division Head of Novartis Pharmaceuticals David Epstein as well as the Q&A; session. --------------- All speeches as well as the Q&A; session are available in the GOMEX Newsroom at http://bit.ly/cmsgomex_en - free download for editorial use. -
Novartis-GV: Die Wut der Aktionäre
Die Messer sind gewetzt: Daniel Vasella, nur noch heute Präsident von Novartis, tritt vor über 2688 Aktionäre. Die Mehrheit ist ihm schlecht gesinnt und wettert gegen Daniel Vasella. -
Novartis' new heart drug potential game changer: CEO
Joe Jimenez, Novartis CEO, discusses the pharma company's quarterly results and its new heart failure drug, Entresto. -
120 secondes - Le procès de Novartis en Inde
120 secondes - L'invité du jour : Reto Zenhäusern, membre de la direction générale de Novartis, évoque le procès intenté par sa compagnie en Inde pour empêcher la vente de génériques de son médicament anticancéreux Glivec®. Retrouvez toutes les vidéos de 120 secondes sur : http://www.rts.ch/couleur3/programmes/120-secondes -
Novartis Joins Google To Make Smart Contact Lens
Google has found a partner, health care company Novartis, to bring its smart contact lens prototype to the consumer market. Follow Lauren Gores: http://www.twitter.com/LaurenGores See more at http://www.newsy.com Sources: Google Blog http://googleblog.blogspot.com/2014/01/introducing-our-smart-contact-lens.html Novartis https://www.youtube.com/watch?v=XuKfFoJqKRg&list;=UUSg28bDoEVjVegY4-htQM7A Bloomberg http://www.bloomberg.com/news/2014-07-15/novartis-allies-google-with-to-make-smart-contact-lens.html Novartis http://www.novartis.com/newsroom/media-releases/en/2014/1824836.shtml Mashable http://mashable.com/2014/07/15/google-novartis-contact-lenses/ CNET http://www.cnet.com/news/google-extends-smart-lens-tech-for-those-with-diabetes-vision-problems/ Image via: Google http://www.n... -
Novartis CEO Joe Jimenez: The best advice I ever got
What's the best advice you've ever been given? In the first clip for Fast Company's "30 Second MBA" video series, Novartis CEO Joe Jimenez shares his most valuable feedback and how he used this advice to turn an unexpected career move into a learning experience. Check it out at FastCompany.com: http://www.fastcompany.com/mba/profile/joe-jimenez © 2012 Novartis AG -
How Novartis and Big Pharma maximise profits with evergreening - Truthloader
Adam explains how drug companies may manipulate patent laws to maximise profits - a process known as "evergreening" - and speaks to Aziz Rehman from Médecins Sans Frontières about what a recent ruling in India could mean for such practices in the future. We initially uploaded this video yesterday but it was in mono - hopefully it should come in both your ears this time. Médecins Sans Frontières' YouTube channel: http://www.youtube.com/user/MSF Subscribe to our channel: http://bit.ly/TRUsub Follow us on Facebook: http://facebook.com/truthloader Follow us on Twitter: http://twitter.com/truthloader Read our reddit: http://reddit.com/r/truthloader Truthloader is a channel dedicated to citizen journalism. We find the best examples of crowd-sourced video and independent content, then use ... -
Joe Jimenez, CEO of Novartis at Berkeley-Haas
- Order: Reorder
- Duration: 57:40
- Updated: 26 Sep 2013
- views: 14612
Joe Jimenez, Haas MBA 84 and CEO of Novartis, spoke to the Berkeley-Haas community about leadership and the pharmaceutical industry in his Dean's Speaker Series...
Joe Jimenez, Haas MBA 84 and CEO of Novartis, spoke to the Berkeley-Haas community about leadership and the pharmaceutical industry in his Dean's Speaker Series talk on September 24, 2013.
wn.com/Joe Jimenez, Ceo Of Novartis At Berkeley Haas
Joe Jimenez, Haas MBA 84 and CEO of Novartis, spoke to the Berkeley-Haas community about leadership and the pharmaceutical industry in his Dean's Speaker Series talk on September 24, 2013.
- published: 26 Sep 2013
- views: 14612
Long Live Life: Reflecting on the Novartis mission
- Order: Reorder
- Duration: 3:27
- Updated: 25 Oct 2013
- views: 33677
Long Live Life is a collective expression for what Novartis stands for and believes in as a company -- that normal life is extraordinary and that every day we f...
Long Live Life is a collective expression for what Novartis stands for and believes in as a company -- that normal life is extraordinary and that every day we fight to protect normal life. That's what it means to care and to cure.
wn.com/Long Live Life Reflecting On The Novartis Mission
Novartis Mission
- Order: Reorder
- Duration: 1:17
- Updated: 27 Jan 2016
- views: 1276
Reimagining Medicine. Our mission is to discover new ways to improve and extend people’s lives. We use science-based innovation to address some of society’s mos...
Reimagining Medicine. Our mission is to discover new ways to improve and extend people’s lives. We use science-based innovation to address some of society’s most challenging healthcare issues. We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible.
© 2016 Novartis AG
wn.com/Novartis Mission
Reimagining Medicine. Our mission is to discover new ways to improve and extend people’s lives. We use science-based innovation to address some of society’s most challenging healthcare issues. We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible.
© 2016 Novartis AG
- published: 27 Jan 2016
- views: 1276
Inauguration of Novartis Knowledge City
- Order: Reorder
- Duration: 11:49
- Updated: 18 Dec 2015
- views: 4641
IT & Panchayat Raj Minister Sri KT Rama Rao inaugurated Novartis Knowledge City at Hyderabad.
17-12-2015
IT & Panchayat Raj Minister Sri KT Rama Rao inaugurated Novartis Knowledge City at Hyderabad.
17-12-2015
wn.com/Inauguration Of Novartis Knowledge City
Inauguration of Novartis Knowledge City - Novartis Knowledge City || Novartis Knowledge City
- Order: Reorder
- Duration: 11:41
- Updated: 23 Dec 2015
- views: 103
Telangana's Information Technology Minister K. Tarakarama Rao inaugurated the new complex of Novartis Global Service Centers (NGSC), a nine-storied structure wi...
Telangana's Information Technology Minister K. Tarakarama Rao inaugurated the new complex of Novartis Global Service Centers (NGSC), a nine-storied structure with a gross area of 800,000 square feet, or sufficient space to enable Novartis to absorb future growth.
The other global NGSCs are in Mexico City, Dublin, Prague, Kuala Lumpur.
Download iDreamMedia app and enjoy all of these videos through your mobiles/tablets:
iPhone: http://tinyurl.com/lvu3wyx
iPad: http://tinyurl.com/ls4tee8
Android: http://tinyurl.com/m78hwyv
For More Latest Videos, please check out
Breaking News: http://goo.gl/rXYPWO
Full Movies: http://goo.gl/mDS9IQ
Film Trailers & Events: http://goo.gl/vQ6oKl
Comedy Scenes: http://goo.gl/bpCWe2
Action Scenes: http://goo.gl/Dk3JPF
wn.com/Inauguration Of Novartis Knowledge City Novartis Knowledge City || Novartis Knowledge City
Telangana's Information Technology Minister K. Tarakarama Rao inaugurated the new complex of Novartis Global Service Centers (NGSC), a nine-storied structure with a gross area of 800,000 square feet, or sufficient space to enable Novartis to absorb future growth.
The other global NGSCs are in Mexico City, Dublin, Prague, Kuala Lumpur.
Download iDreamMedia app and enjoy all of these videos through your mobiles/tablets:
iPhone: http://tinyurl.com/lvu3wyx
iPad: http://tinyurl.com/ls4tee8
Android: http://tinyurl.com/m78hwyv
For More Latest Videos, please check out
Breaking News: http://goo.gl/rXYPWO
Full Movies: http://goo.gl/mDS9IQ
Film Trailers & Events: http://goo.gl/vQ6oKl
Comedy Scenes: http://goo.gl/bpCWe2
Action Scenes: http://goo.gl/Dk3JPF
- published: 23 Dec 2015
- views: 103
Diversity & Inclusion at Novartis
- Order: Reorder
- Duration: 3:33
- Updated: 20 Nov 2014
- views: 12613
Each of us is different. At Novartis, we aspire to move beyond stereotypes, assumptions and bias to bring these differences together every day, so we can see th...
Each of us is different. At Novartis, we aspire to move beyond stereotypes, assumptions and bias to bring these differences together every day, so we can see the world through the eyes of our patients and customers, in our quest to make their lives longer and healthier.
For more information: http://www.novartis.com/careers/diversity-inclusion/index.shtml
(c) Novartis 2014
wn.com/Diversity Inclusion At Novartis
Each of us is different. At Novartis, we aspire to move beyond stereotypes, assumptions and bias to bring these differences together every day, so we can see the world through the eyes of our patients and customers, in our quest to make their lives longer and healthier.
For more information: http://www.novartis.com/careers/diversity-inclusion/index.shtml
(c) Novartis 2014
- published: 20 Nov 2014
- views: 12613
Why Novartis focuses on cancer drugs
- Order: Reorder
- Duration: 3:22
- Updated: 28 Mar 2013
- views: 1634
CEO Joseph Jimenez says oncology will be an area of great medical breakthroughs in the next five to ten years.
CEO Joseph Jimenez says oncology will be an area of great medical breakthroughs in the next five to ten years.
wn.com/Why Novartis Focuses On Cancer Drugs
CEO Joseph Jimenez says oncology will be an area of great medical breakthroughs in the next five to ten years.
- published: 28 Mar 2013
- views: 1634
Joseph Jimenez, CEO Novartis
- Order: Reorder
- Duration: 2:48
- Updated: 27 Jan 2016
- views: 144
Die Novartis-Aktie ist am Mittwoch das grosse Thema am Schweizer Aktienmarkt. Im Video-Interview sagt CEO Joseph Jimenez, was er mit der Problemsparte Alcon vor...
Die Novartis-Aktie ist am Mittwoch das grosse Thema am Schweizer Aktienmarkt. Im Video-Interview sagt CEO Joseph Jimenez, was er mit der Problemsparte Alcon vorhat und in welchen Bereichen viel Wachstum schlummert.
wn.com/Joseph Jimenez, Ceo Novartis
Die Novartis-Aktie ist am Mittwoch das grosse Thema am Schweizer Aktienmarkt. Im Video-Interview sagt CEO Joseph Jimenez, was er mit der Problemsparte Alcon vorhat und in welchen Bereichen viel Wachstum schlummert.
- published: 27 Jan 2016
- views: 144
Novartis and Glaxo Deal Reshapes Pharma Industry
- Order: Reorder
- Duration: 3:54
- Updated: 22 Apr 2014
- views: 4665
Novartis completed about $25 billion of transactions in its product portfolios, including the sale of two units to British-based GlaxoSmithKline. Hester Plumrid...
Novartis completed about $25 billion of transactions in its product portfolios, including the sale of two units to British-based GlaxoSmithKline. Hester Plumridge explains why the Swiss company is doing these deals now and what this means for the pharmaceutical industry.
Subscribe to the WSJ channel here:
http://bit.ly/14Q81Xy
Visit the WSJ channel for more video:
https://www.youtube.com/wsjdigitalnetwork
More from the Wall Street Journal:
Visit WSJ.com: http://online.wsj.com/home-page
Follow WSJ on Facebook:
http://www.facebook.com/wsjlive
Follow WSJ on Google+: https://plus.google.com/+wsj/posts
Follow WSJ on Twitter: https://twitter.com/WSJLive
Follow WSJ on Instagram: http://instagram.com/wsj
Follow WSJ on Pinterest: http://www.pinterest.com/wsj/
Follow WSJ on Tumblr: http://www.tumblr.com/tagged/wall-street-journal
wn.com/Novartis And Glaxo Deal Reshapes Pharma Industry
Novartis completed about $25 billion of transactions in its product portfolios, including the sale of two units to British-based GlaxoSmithKline. Hester Plumridge explains why the Swiss company is doing these deals now and what this means for the pharmaceutical industry.
Subscribe to the WSJ channel here:
http://bit.ly/14Q81Xy
Visit the WSJ channel for more video:
https://www.youtube.com/wsjdigitalnetwork
More from the Wall Street Journal:
Visit WSJ.com: http://online.wsj.com/home-page
Follow WSJ on Facebook:
http://www.facebook.com/wsjlive
Follow WSJ on Google+: https://plus.google.com/+wsj/posts
Follow WSJ on Twitter: https://twitter.com/WSJLive
Follow WSJ on Instagram: http://instagram.com/wsj
Follow WSJ on Pinterest: http://www.pinterest.com/wsj/
Follow WSJ on Tumblr: http://www.tumblr.com/tagged/wall-street-journal
- published: 22 Apr 2014
- views: 4665
Novartis CEO on partnering with Google on contact lenses
- Order: Reorder
- Duration: 5:08
- Updated: 21 Oct 2015
- views: 197
Novartis CEO Joseph Jimenez on innovation in health care, integrating GlaxoSmithKline assets and concerns over the potential regulation of pharmaceutical pricin...
Novartis CEO Joseph Jimenez on innovation in health care, integrating GlaxoSmithKline assets and concerns over the potential regulation of pharmaceutical pricing.
Watch Maria Bartiromo talk about Health Care and Strategy on Mornings With Maria.
wn.com/Novartis Ceo On Partnering With Google On Contact Lenses
Novartis CEO Joseph Jimenez on innovation in health care, integrating GlaxoSmithKline assets and concerns over the potential regulation of pharmaceutical pricing.
Watch Maria Bartiromo talk about Health Care and Strategy on Mornings With Maria.
- published: 21 Oct 2015
- views: 197
Novartis International BioCamp 2015
- Order: Reorder
- Duration: 5:08
- Updated: 10 Sep 2015
- views: 2838
Novartis International BioCamp 2015 shows student interactions during a 3.5 day pioneering leadership seminar at the Novartis Campus in Basel.
© 2015 Novartis...
Novartis International BioCamp 2015 shows student interactions during a 3.5 day pioneering leadership seminar at the Novartis Campus in Basel.
© 2015 Novartis AG
wn.com/Novartis International Biocamp 2015
Novartis International BioCamp 2015 shows student interactions during a 3.5 day pioneering leadership seminar at the Novartis Campus in Basel.
© 2015 Novartis AG
- published: 10 Sep 2015
- views: 2838
Novartis International Biotechnology Leadership Camp 2014
- Order: Reorder
- Duration: 5:56
- Updated: 05 Sep 2014
- views: 10816
Novartis International Biotechnology Leadership Camp (BioCamp) is a pioneering three-day seminar that offers top university students the opportunity to apply th...
Novartis International Biotechnology Leadership Camp (BioCamp) is a pioneering three-day seminar that offers top university students the opportunity to apply their knowledge to current trends and challenges of the biotechnology and healthcare industry. The 2014 BioCamp welcomed over 60 participants from 25 countries to Novartis Headquarters in Basel, Switzerland, from August 25 to August 27, 2014.
Learn more about the Novartis BioCamp: http://www.novartis.com/careers/biocamp/index.shtml
wn.com/Novartis International Biotechnology Leadership Camp 2014
Novartis International Biotechnology Leadership Camp (BioCamp) is a pioneering three-day seminar that offers top university students the opportunity to apply their knowledge to current trends and challenges of the biotechnology and healthcare industry. The 2014 BioCamp welcomed over 60 participants from 25 countries to Novartis Headquarters in Basel, Switzerland, from August 25 to August 27, 2014.
Learn more about the Novartis BioCamp: http://www.novartis.com/careers/biocamp/index.shtml
- published: 05 Sep 2014
- views: 10816
Novartis/GSK -- expensive restructuring?
- Order: Reorder
- Duration: 2:53
- Updated: 22 Apr 2014
- views: 2705
GlaxoSmithKline has struck a three-way agreement worth $16bn with Novartis to reorganise their businesses. Lex's Joseph Cotterill and Robert Armstrong discuss w...
GlaxoSmithKline has struck a three-way agreement worth $16bn with Novartis to reorganise their businesses. Lex's Joseph Cotterill and Robert Armstrong discuss whether the reorganisation aids a prime objective of drugmakers: selling more drugs.
For more video content from the Financial Times, visit http://www.FT.com/video
Subscribe to the Financial Times on YouTube; http://goo.gl/vUQx5k
Twitter https://twitter.com/ftvideo
Facebook https://www.facebook.com/financialtimes
wn.com/Novartis Gsk Expensive Restructuring
GlaxoSmithKline has struck a three-way agreement worth $16bn with Novartis to reorganise their businesses. Lex's Joseph Cotterill and Robert Armstrong discuss whether the reorganisation aids a prime objective of drugmakers: selling more drugs.
For more video content from the Financial Times, visit http://www.FT.com/video
Subscribe to the Financial Times on YouTube; http://goo.gl/vUQx5k
Twitter https://twitter.com/ftvideo
Facebook https://www.facebook.com/financialtimes
- published: 22 Apr 2014
- views: 2705
A look inside the Genomics Institute of the Novartis Research Foundation
- Order: Reorder
- Duration: 3:04
- Updated: 10 Sep 2015
- views: 1676
Genomics Institute of the Novartis Research Foundation (GNF) researchers use cutting-edge technology—including automation and robotics developed at the institut...
Genomics Institute of the Novartis Research Foundation (GNF) researchers use cutting-edge technology—including automation and robotics developed at the institute—to take advantage of emerging large-scale, data-rich fields for drug discovery.
wn.com/A Look Inside The Genomics Institute Of The Novartis Research Foundation
Genomics Institute of the Novartis Research Foundation (GNF) researchers use cutting-edge technology—including automation and robotics developed at the institute—to take advantage of emerging large-scale, data-rich fields for drug discovery.
- published: 10 Sep 2015
- views: 1676
120 secondes - Novartis restructure son portefeuille d'activités
- Order: Reorder
- Duration: 4:10
- Updated: 23 Apr 2014
- views: 12605
120 secondes : Reto Zenhäusern, membre de la direction générale de Novartis, commente l'importante transformation annoncée hier par le CEO de l'entreprise Joe J...
120 secondes : Reto Zenhäusern, membre de la direction générale de Novartis, commente l'importante transformation annoncée hier par le CEO de l'entreprise Joe Jimenez.
Retrouvez toutes les vidéos de 120 secondes sur : http://www.rts.ch/couleur3/programmes/120-secondes
Retrouvez la Radio Télévision Suisse:
Site internet : http://www.rts.ch/
Facebook : https://www.facebook.com/rts.ch
Twitter : https://twitter.com/radiotelesuisse
Instagram : http://instagram.com/radiotelevisionsuisse
Google+ : https://plus.google.com/+RadioTelevisionSuisse/posts
wn.com/120 Secondes Novartis Restructure Son Portefeuille D'Activités
120 secondes : Reto Zenhäusern, membre de la direction générale de Novartis, commente l'importante transformation annoncée hier par le CEO de l'entreprise Joe Jimenez.
Retrouvez toutes les vidéos de 120 secondes sur : http://www.rts.ch/couleur3/programmes/120-secondes
Retrouvez la Radio Télévision Suisse:
Site internet : http://www.rts.ch/
Facebook : https://www.facebook.com/rts.ch
Twitter : https://twitter.com/radiotelesuisse
Instagram : http://instagram.com/radiotelevisionsuisse
Google+ : https://plus.google.com/+RadioTelevisionSuisse/posts
- published: 23 Apr 2014
- views: 12605
Annual Press Conference 2015 - Novartis AG
- Order: Reorder
- Duration: 32:15
- Updated: 27 Jan 2015
- views: 726
Novartis AG today announced its financial results for the fourth quarter and full year ended December 31, 2014. Watch the entire Press Conference with speeches ...
Novartis AG today announced its financial results for the fourth quarter and full year ended December 31, 2014. Watch the entire Press Conference with speeches from CEO Joseph Jimenez, CFO Harry Kirsch and Division Head of Novartis Pharmaceuticals David Epstein as well as the Q&A; session.
---------------
All speeches as well as the Q&A; session are available in the GOMEX Newsroom at http://bit.ly/cmsgomex_en - free download for editorial use.
wn.com/Annual Press Conference 2015 Novartis Ag
Novartis AG today announced its financial results for the fourth quarter and full year ended December 31, 2014. Watch the entire Press Conference with speeches from CEO Joseph Jimenez, CFO Harry Kirsch and Division Head of Novartis Pharmaceuticals David Epstein as well as the Q&A; session.
---------------
All speeches as well as the Q&A; session are available in the GOMEX Newsroom at http://bit.ly/cmsgomex_en - free download for editorial use.
- published: 27 Jan 2015
- views: 726
Novartis-GV: Die Wut der Aktionäre
- Order: Reorder
- Duration: 2:32
- Updated: 22 Feb 2013
- views: 5786
Die Messer sind gewetzt: Daniel Vasella, nur noch heute Präsident von Novartis, tritt vor über 2688 Aktionäre. Die Mehrheit ist ihm schlecht gesinnt und wettert...
Die Messer sind gewetzt: Daniel Vasella, nur noch heute Präsident von Novartis, tritt vor über 2688 Aktionäre. Die Mehrheit ist ihm schlecht gesinnt und wettert gegen Daniel Vasella.
wn.com/Novartis Gv Die Wut Der Aktionäre
Die Messer sind gewetzt: Daniel Vasella, nur noch heute Präsident von Novartis, tritt vor über 2688 Aktionäre. Die Mehrheit ist ihm schlecht gesinnt und wettert gegen Daniel Vasella.
- published: 22 Feb 2013
- views: 5786
Novartis' new heart drug potential game changer: CEO
- Order: Reorder
- Duration: 2:35
- Updated: 21 Jul 2015
- views: 485
Joe Jimenez, Novartis CEO, discusses the pharma company's quarterly results and its new heart failure drug, Entresto.
Joe Jimenez, Novartis CEO, discusses the pharma company's quarterly results and its new heart failure drug, Entresto.
wn.com/Novartis' New Heart Drug Potential Game Changer Ceo
Joe Jimenez, Novartis CEO, discusses the pharma company's quarterly results and its new heart failure drug, Entresto.
- published: 21 Jul 2015
- views: 485
120 secondes - Le procès de Novartis en Inde
- Order: Reorder
- Duration: 4:25
- Updated: 13 Sep 2012
- views: 19200
120 secondes - L'invité du jour : Reto Zenhäusern, membre de la direction générale de Novartis, évoque le procès intenté par sa compagnie en Inde pour empêcher...
120 secondes - L'invité du jour : Reto Zenhäusern, membre de la direction générale de Novartis, évoque le procès intenté par sa compagnie en Inde pour empêcher la vente de génériques de son médicament anticancéreux Glivec®.
Retrouvez toutes les vidéos de 120 secondes sur : http://www.rts.ch/couleur3/programmes/120-secondes
wn.com/120 Secondes Le Procès De Novartis En Inde
120 secondes - L'invité du jour : Reto Zenhäusern, membre de la direction générale de Novartis, évoque le procès intenté par sa compagnie en Inde pour empêcher la vente de génériques de son médicament anticancéreux Glivec®.
Retrouvez toutes les vidéos de 120 secondes sur : http://www.rts.ch/couleur3/programmes/120-secondes
- published: 13 Sep 2012
- views: 19200
Novartis Joins Google To Make Smart Contact Lens
- Order: Reorder
- Duration: 2:07
- Updated: 15 Jul 2014
- views: 9050
Google has found a partner, health care company Novartis, to bring its smart contact lens prototype to the consumer market.
Follow Lauren Gores: http://www.twi...
Google has found a partner, health care company Novartis, to bring its smart contact lens prototype to the consumer market.
Follow Lauren Gores: http://www.twitter.com/LaurenGores
See more at http://www.newsy.com
Sources:
Google Blog http://googleblog.blogspot.com/2014/01/introducing-our-smart-contact-lens.html
Novartis https://www.youtube.com/watch?v=XuKfFoJqKRg&list;=UUSg28bDoEVjVegY4-htQM7A
Bloomberg http://www.bloomberg.com/news/2014-07-15/novartis-allies-google-with-to-make-smart-contact-lens.html
Novartis http://www.novartis.com/newsroom/media-releases/en/2014/1824836.shtml
Mashable http://mashable.com/2014/07/15/google-novartis-contact-lenses/
CNET http://www.cnet.com/news/google-extends-smart-lens-tech-for-those-with-diabetes-vision-problems/
Image via: Google
http://www.novartis.com/newsroom/media-releases/en/2014/1824836.shtml
wn.com/Novartis Joins Google To Make Smart Contact Lens
Google has found a partner, health care company Novartis, to bring its smart contact lens prototype to the consumer market.
Follow Lauren Gores: http://www.twitter.com/LaurenGores
See more at http://www.newsy.com
Sources:
Google Blog http://googleblog.blogspot.com/2014/01/introducing-our-smart-contact-lens.html
Novartis https://www.youtube.com/watch?v=XuKfFoJqKRg&list;=UUSg28bDoEVjVegY4-htQM7A
Bloomberg http://www.bloomberg.com/news/2014-07-15/novartis-allies-google-with-to-make-smart-contact-lens.html
Novartis http://www.novartis.com/newsroom/media-releases/en/2014/1824836.shtml
Mashable http://mashable.com/2014/07/15/google-novartis-contact-lenses/
CNET http://www.cnet.com/news/google-extends-smart-lens-tech-for-those-with-diabetes-vision-problems/
Image via: Google
http://www.novartis.com/newsroom/media-releases/en/2014/1824836.shtml
- published: 15 Jul 2014
- views: 9050
Novartis CEO Joe Jimenez: The best advice I ever got
- Order: Reorder
- Duration: 0:38
- Updated: 21 Dec 2012
- views: 13369
What's the best advice you've ever been given? In the first clip for Fast Company's "30 Second MBA" video series, Novartis CEO Joe Jimenez shares his most valua...
What's the best advice you've ever been given? In the first clip for Fast Company's "30 Second MBA" video series, Novartis CEO Joe Jimenez shares his most valuable feedback and how he used this advice to turn an unexpected career move into a learning experience. Check it out at FastCompany.com: http://www.fastcompany.com/mba/profile/joe-jimenez
© 2012 Novartis AG
wn.com/Novartis Ceo Joe Jimenez The Best Advice I Ever Got
What's the best advice you've ever been given? In the first clip for Fast Company's "30 Second MBA" video series, Novartis CEO Joe Jimenez shares his most valuable feedback and how he used this advice to turn an unexpected career move into a learning experience. Check it out at FastCompany.com: http://www.fastcompany.com/mba/profile/joe-jimenez
© 2012 Novartis AG
- published: 21 Dec 2012
- views: 13369
How Novartis and Big Pharma maximise profits with evergreening - Truthloader
- Order: Reorder
- Duration: 3:18
- Updated: 03 Apr 2013
- views: 30439
Adam explains how drug companies may manipulate patent laws to maximise profits - a process known as "evergreening" - and speaks to Aziz Rehman from Médecins Sa...
Adam explains how drug companies may manipulate patent laws to maximise profits - a process known as "evergreening" - and speaks to Aziz Rehman from Médecins Sans Frontières about what a recent ruling in India could mean for such practices in the future.
We initially uploaded this video yesterday but it was in mono - hopefully it should come in both your ears this time.
Médecins Sans Frontières' YouTube channel: http://www.youtube.com/user/MSF
Subscribe to our channel: http://bit.ly/TRUsub
Follow us on Facebook:
http://facebook.com/truthloader
Follow us on Twitter:
http://twitter.com/truthloader
Read our reddit:
http://reddit.com/r/truthloader
Truthloader is a channel dedicated to citizen journalism. We find the best examples of crowd-sourced video and independent content, then use our expertise to add context and analysis. We respond to the stories you're interested in, so if you've got a story you'd love us to get to the bottom of, tweet us, Facebook us, or respond to our videos with a comment - and perhaps check out our reddit.
wn.com/How Novartis And Big Pharma Maximise Profits With Evergreening Truthloader
Adam explains how drug companies may manipulate patent laws to maximise profits - a process known as "evergreening" - and speaks to Aziz Rehman from Médecins Sans Frontières about what a recent ruling in India could mean for such practices in the future.
We initially uploaded this video yesterday but it was in mono - hopefully it should come in both your ears this time.
Médecins Sans Frontières' YouTube channel: http://www.youtube.com/user/MSF
Subscribe to our channel: http://bit.ly/TRUsub
Follow us on Facebook:
http://facebook.com/truthloader
Follow us on Twitter:
http://twitter.com/truthloader
Read our reddit:
http://reddit.com/r/truthloader
Truthloader is a channel dedicated to citizen journalism. We find the best examples of crowd-sourced video and independent content, then use our expertise to add context and analysis. We respond to the stories you're interested in, so if you've got a story you'd love us to get to the bottom of, tweet us, Facebook us, or respond to our videos with a comment - and perhaps check out our reddit.
- published: 03 Apr 2013
- views: 30439
Interview: Joseph Jimenez, CEO Novartis & President EFPIA
- Order: Reorder
- Duration: 6:08
- Updated: 12 May 2015
- views: 1680
Interview with Joseph Jimenez on his aspirations for his presidency and the 2015 EFPIA Annual Meetings.
Interview with Joseph Jimenez on his aspirations for his presidency and the 2015 EFPIA Annual Meetings.
wn.com/Interview Joseph Jimenez, Ceo Novartis President Efpia
close fullscreen
- Playlist
- Chat
close fullscreen
- Playlist
- Chat
57:40
Joe Jimenez, CEO of Novartis at Berkeley-Haas
Joe Jimenez, Haas MBA 84 and CEO of Novartis, spoke to the Berkeley-Haas community about l...
published: 26 Sep 2013
Joe Jimenez, CEO of Novartis at Berkeley-Haas
Joe Jimenez, CEO of Novartis at Berkeley-Haas
- Report rights infringement
- published: 26 Sep 2013
- views: 14612
3:27
Long Live Life: Reflecting on the Novartis mission
Long Live Life is a collective expression for what Novartis stands for and believes in as ...
published: 25 Oct 2013
Long Live Life: Reflecting on the Novartis mission
Long Live Life: Reflecting on the Novartis mission
- Report rights infringement
- published: 25 Oct 2013
- views: 33677
1:17
Novartis Mission
Reimagining Medicine. Our mission is to discover new ways to improve and extend people’s l...
published: 27 Jan 2016
Novartis Mission
Novartis Mission
- Report rights infringement
- published: 27 Jan 2016
- views: 1276
11:49
Inauguration of Novartis Knowledge City
IT & Panchayat Raj Minister Sri KT Rama Rao inaugurated Novartis Knowledge City at Hyderab...
published: 18 Dec 2015
Inauguration of Novartis Knowledge City
Inauguration of Novartis Knowledge City
- Report rights infringement
- published: 18 Dec 2015
- views: 4641
11:41
Inauguration of Novartis Knowledge City - Novartis Knowledge City || Novartis Knowledge City
Telangana's Information Technology Minister K. Tarakarama Rao inaugurated the new complex ...
published: 23 Dec 2015
Inauguration of Novartis Knowledge City - Novartis Knowledge City || Novartis Knowledge City
Inauguration of Novartis Knowledge City - Novartis Knowledge City || Novartis Knowledge City
- Report rights infringement
- published: 23 Dec 2015
- views: 103
3:33
Diversity & Inclusion at Novartis
Each of us is different. At Novartis, we aspire to move beyond stereotypes, assumptions an...
published: 20 Nov 2014
Diversity & Inclusion at Novartis
Diversity & Inclusion at Novartis
- Report rights infringement
- published: 20 Nov 2014
- views: 12613
3:22
Why Novartis focuses on cancer drugs
CEO Joseph Jimenez says oncology will be an area of great medical breakthroughs in the nex...
published: 28 Mar 2013
Why Novartis focuses on cancer drugs
Why Novartis focuses on cancer drugs
- Report rights infringement
- published: 28 Mar 2013
- views: 1634
2:48
Joseph Jimenez, CEO Novartis
Die Novartis-Aktie ist am Mittwoch das grosse Thema am Schweizer Aktienmarkt. Im Video-Int...
published: 27 Jan 2016
Joseph Jimenez, CEO Novartis
Joseph Jimenez, CEO Novartis
- Report rights infringement
- published: 27 Jan 2016
- views: 144
3:54
Novartis and Glaxo Deal Reshapes Pharma Industry
Novartis completed about $25 billion of transactions in its product portfolios, including ...
published: 22 Apr 2014
Novartis and Glaxo Deal Reshapes Pharma Industry
Novartis and Glaxo Deal Reshapes Pharma Industry
- Report rights infringement
- published: 22 Apr 2014
- views: 4665
5:08
Novartis CEO on partnering with Google on contact lenses
Novartis CEO Joseph Jimenez on innovation in health care, integrating GlaxoSmithKline asse...
published: 21 Oct 2015
Novartis CEO on partnering with Google on contact lenses
Novartis CEO on partnering with Google on contact lenses
- Report rights infringement
- published: 21 Oct 2015
- views: 197
5:08
Novartis International BioCamp 2015
Novartis International BioCamp 2015 shows student interactions during a 3.5 day pioneering...
published: 10 Sep 2015
Novartis International BioCamp 2015
Novartis International BioCamp 2015
- Report rights infringement
- published: 10 Sep 2015
- views: 2838
5:56
Novartis International Biotechnology Leadership Camp 2014
Novartis International Biotechnology Leadership Camp (BioCamp) is a pioneering three-day s...
published: 05 Sep 2014
Novartis International Biotechnology Leadership Camp 2014
Novartis International Biotechnology Leadership Camp 2014
- Report rights infringement
- published: 05 Sep 2014
- views: 10816
2:53
Novartis/GSK -- expensive restructuring?
GlaxoSmithKline has struck a three-way agreement worth $16bn with Novartis to reorganise t...
published: 22 Apr 2014
Novartis/GSK -- expensive restructuring?
Novartis/GSK -- expensive restructuring?
- Report rights infringement
- published: 22 Apr 2014
- views: 2705
3:04
A look inside the Genomics Institute of the Novartis Research Foundation
Genomics Institute of the Novartis Research Foundation (GNF) researchers use cutting-edge ...
published: 10 Sep 2015
A look inside the Genomics Institute of the Novartis Research Foundation
A look inside the Genomics Institute of the Novartis Research Foundation
- Report rights infringement
- published: 10 Sep 2015
- views: 1676
Joe Jimenez, CEO of Novartis at Berkeley-Haas...
Long Live Life: Reflecting on the Novartis mission...
Novartis Mission...
Inauguration of Novartis Knowledge City...
Inauguration of Novartis Knowledge City - Novartis...
Diversity & Inclusion at Novartis...
Why Novartis focuses on cancer drugs...
Joseph Jimenez, CEO Novartis...
Novartis and Glaxo Deal Reshapes Pharma Industry...
Novartis CEO on partnering with Google on contact ...
Novartis International BioCamp 2015...
Novartis International Biotechnology Leadership Ca...
Novartis/GSK -- expensive restructuring?...
A look inside the Genomics Institute of the Novart...
120 secondes - Novartis restructure son portefeuil...
Annual Press Conference 2015 - Novartis AG...
Novartis-GV: Die Wut der Aktionäre...
Novartis' new heart drug potential game changer: C...
120 secondes - Le procès de Novartis en Inde...
Novartis Joins Google To Make Smart Contact Lens...
Novartis CEO Joe Jimenez: The best advice I ever g...
How Novartis and Big Pharma maximise profits with ...
Interview: Joseph Jimenez, CEO Novartis & Presiden...
photo: WN / Yolanda Leyba
Texas Man Sues For Right To Marry Computer In Bid To Overturn Same-Sex Marriage
Edit WorldNews.com 19 Apr 2016
A Texas man is trying to overturn legal same-sex marriage by suing for the right to marry his laptop computer, according to a story from the Midland Reporter-Telegram published on RawStory.com.Chris Sevier has filed a lawsuit against the Harris County district clerk, Gov ... “This is about who is on the right side of reality....
photo: NASA / JPL-Caltech/UCLA/MPS/DLR/IDA
NASA's Dawn Probe Captures Bright Craters In Closeup With Dwarf Planet Ceres
Edit WorldNews.com 20 Apr 2016
NASA’s Dawn space probe has captured new images of bright craters on Ceres, the dwarf planet that lies between Jupiter and Mars, according to a published report Tuesday.The images were taken 240 miles from Ceres, the closest the spacecraft has come to the celestial body. At its lowest altitude yet, the probe has captured photos of the dwarf planet's strange bright spots....
photo: AP / Jack Guez, Pool
Israeli Military Finds, Destroys Hamas Tunnel Burrowing 30 Meters Into Israeli Territory
Edit WorldNews.com 19 Apr 2016
Hamas officials are minimizing news of Israel’s discovery of an attack tunnel reaching into Israeli territory that was destroyed by the military, Breitbart Jerusalem reported Tuesday. “The Israeli statements are motivated by domestic politics ... Since its discovery, the military has destroyed the tunnel’s openings on both sides of the border fence....
photo: Creative Commons / Chris 73
India still wants the UK to give the Kohinoor diamond back
Edit CNN 20 Apr 2016
(CNN)The Indian government is making "all possible efforts" to retrieve the Kohinoor diamond contrary to reported comments from the country's Solicitor General that the rare historical stone was given as a gift to the United Kingdom and not stolen ... The country's highest court is deciding on the issue after an Indian NGO filed a petition asking the court to bid for the diamond's return. Sketches of the Kohinoor from circa 1860 ... ....
photo: AP / Steven Senne
Criminal charges today in Flint water crisis
Edit Detroit Free Press 20 Apr 2016
Sources. Charges to be brought against officials with the Michigan Department of Environmental Quality and City of Flint ... ....
« back to news headlines
Glaxo May Need to Boost Pay to Lure U.S. Candidates for CEO Role
Edit Bloomberg 20 Apr 2016
industry experience ... Among European peers, he brings home less than Novartis AG’s Joe Jimenez and Sanofi’s Olivier Brandicourt ... To benchmark executive pay, Glaxo’s board compares it with a group of 11 global drugmakers that includes Pfizer, Sanofi, Novartis and Merck & Co., as well as other members of the U.K.’s benchmark FTSE 100 index, such as BP Plc, British American Tobacco Plc and Royal Dutch Shell Plc.Regional Comparisons ... ....
Press Release from Business Wire : WIN Consortium
Edit The Times of India 20 Apr 2016
VILLEJUIF, (BSW) - ... WIN 2016's symposium will be of exceptional value, as it will address very challenging and controversial themes. Precision medicine, as announced by the US President Barack Obama, has become a key objective shared by the oncology community ... Schilsky (ASCO®'s Chief Medical Officer and Chairman of WIN Scientific Advisory Board), Razelle Kurzrock (UCSD), William Sellers (Novartis), John Mendelsohn and many others....
Genmab Updates Financial Guidance for 2016 (Genmab A/S)
Edit Public Technologies 20 Apr 2016
(Source. Genmab A/S). Company Announcement Genmab improves financial guidance for 2016 Improvement driven by DARZALEX sales Rapid uptake of the product since launch. Copenhagen, Denmark; April 20, 2016 -Genmab A/S (Nasdaq Copenhagen. GEN) announced today that it is improving its financial guidance published on February 17, 2016 ... and the rapid uptake of the product since launch ... T ... Arzerra is a trademark of Novartis AG or its affiliates ... 19....
Genmab Updates Financial Guidance for 2016
Edit Stockhouse 20 Apr 2016
COPENHAGEN, Denmark, April 20, 2016 (GLOBE NEWSWIRE) -- Company Announcement Genmab improves financial guidance for 2016 Improvement driven by DARZALEX(r) sales Rapid uptake of the product since launch. COPENHAGEN, Denmark, April 20, 2016 (GLOBE NEWSWIRE) -- Genmab A/S (Nasdaq Copenhagen ... and the rapid uptake of the product since launch ... Revenue 925 - 975 825 - 875 ... T ... Arzerra(r) is a trademark of Novartis AG or its affiliates ... MAbs....
Novartis chief fights to restore faith
Edit Swissinfo 19 Apr 2016
Joe Jimenez is facing a battle to restore investor confidence in Novartis, after a series of setbacks which have sent shares in the Swiss pharma group down more than a quarter in the past year....
The World Market for Cancer Therapeutics - Key Players include Novartis, Pfizer & Bayer - ...
Edit Business Wire 19 Apr 2016
DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "The World Market for Cancer Therapeutics (Monoclonal Antibodies, TKIs, Vaccines, Cytokines, Gene Therapy, Chemotherapy, Others), Phase I- III Pipeline Analysis, Markets by Segment" report to their offering. This report presents a detailed picture of the market for cancer drugs, with a focus on novel therapies ... ....
Advances in Inhaled Drug Delivery Offer Major Benefits to Patients, Chief Scientific Officer for Pulmatrix Explains in Article (Pulmatrix Inc)
Edit Public Technologies 19 Apr 2016
(Source. Pulmatrix Inc) ... Writing in ONdrugDelivery Magazine, CSO David L ... LEXINGTON, Mass., April 19, 2016/PRNewswire / -- Pulmatrix, Inc. (NASDAQ ... Hava describes, Novartis AG has developed an of the antibiotic tobramycin, while Gilead has a product with a second antibiotic, aztreonam ... That's why scientists and companies, such as Novartis, Acorda Therapeutics, and Savara, are developing formulations using dry powders that can be inhaled....
Illinois Tech Offering One-Day Creative Problem Solving Workshop – July 13 (Illinois Institute of Technology)
Edit Public Technologies 19 Apr 2016
(Source. Illinois Institute of Technology). Illinois Tech is offering a one-day Creative Problem Solving Workshop on Wednesday, July 13 from 9 a.m.-4 p.m. at the Illinois Tech Rice Campus in Wheaton, Ill ... Organizations teach their teams how to fill out expense accounts, use software, complete employee reviews, and conduct interviews ... He has held senior positions at EquiTrust Life, Walgreens, Zurich Financial, Novartis and Honeywell....
Model N To Host Life Sciences Commercial and Pricing Innovation Forum in Venice, Italy (Model N Inc)
Edit Public Technologies 19 Apr 2016
(Source. Model N Inc). Leading Pharmaceutical and MedTech Executives to Share Best Practices in Global Pricing Innovation and Commercial Excellence to Drive Revenue. REDWOOD CITY, Calif. - April 19, 2016 - Model N, Inc. (NYSE ... Sessions include ... Model N is a trusted partner to some of the world's largest brands, including Johnson & Johnson, AstraZeneca, Boston Scientific, Novartis, Ortho Clinical Diagnostics, Atmel, Fairchild and Marvell....
Tuesday Papers: Morgan Stanley profit falls by half
Edit Citywire 19 Apr 2016
Top stories. Financial Times. Morgan Stanley slashed pay in the first quarter, delivering results that beat analysts’ expectations despite big falls in revenues from bond trading and weak performances from wealth and asset management ... Joe Jimenez is facing a battle to restore investor confidence in Novartis after a series of setbacks which have sent shares in the Swiss pharmaceuticals group down more than a quarter in the past year ... ....
S&P;, Dow cling to gains; Nasdaq lower as Illumina, Netflix weigh
Edit Yahoo Daily News 19 Apr 2016
U.S. stocks traded mixed Tuesday, amid a rise in oil prices, as declines in tech stocks weighed after major earnings reports ... U.S ... ET ... ET ... Alphabet, Microsoft, General Motors, Visa, Starbucks, Bank of NY Mellon, Biogen, Under Armour, Southwest Air, Stanley Black and Decker, Imax, Novartis, Union Paicific, DR Horton, Fifth Third, Johnson Controls, Pulte Group, Polaris, Alaska Air, Verizon, Travelers, E*Trade, Norfolk Southern, Boston Beer....
BioLineRx Announces Presentation of Detailed Mechanism of Action Data for Lead Oncology Platform at AACR 2016 (BioLineRX Ltd)
Edit Public Technologies 19 Apr 2016
(Source. BioLineRX Ltd). TEL AVIV, Israel, April 19, 2016 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE ... In addition, BioLineRx has a strategic collaboration with Novartis for the co-development of selected Israeli-sourced novel drug candidates, and has recently signed a collaboration agreement with MSD (known as Merck in the US and Canada) to run a Phase 2 study in pancreatic cancer using the combination of BL-8040 and Merck's KEYTRUDA....
Ash Stevens Honors Cancer Research Award Winner - James E. Bradner, MD, Novartis Institutes for ...
Edit PR Newswire 18 Apr 2016- 1
- 2
- 3
- 4
- 5
- Next page »
